Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its nexiguran ziclumeran (nex-z) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. Intellia shares were up more than 4 percent in pre-market.
Hereditary ATTR amyloidosis, caused by a mutation in the transthyretin (TTR) gene, is a progressive disorder characterized by the buildup of abnormal protein deposits in body's organs and tissues.
Nex-z is a CRISPR-based investigational therapy designed as a single-dose treatment for ATTR amyloidosis with polyneuropathy.
RMAT designation was granted based on interim data from the Phase 1 study which showed one-time treatment with nex-z led to rapid, deep and durable TTR reduction in patients with ATTR amyloidosis with polyneuropathy.
RMAT designation includes benefits such as early interactions with the FDA, eligibility for priority review and accelerated approval.
As part of a multi-target collaboration with Regeneron, development and commercialization of nex-z is led by Intellia.
Intellia stock had closed at $14.30, up 3.62 percent on Friday. It has traded in the range of $12.82 - $34.87 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.